Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Cornea and External Disease > Study examines impact of donor tissue type on DMEK outcomes
  • Cornea and External Disease

Study examines impact of donor tissue type on DMEK outcomes

Kelsey Moroz

Although pseudophakic donor grafts pose greater challenges during preparation and have longer recovery times compared to phakic and scarred stromal grafts, they can still provide comparable outcomes in Descemet membrane endothelial keratoplasty (DMEK) when complications do not occur, according to a study that advocates for the inclusion of pseudophakic grafts in corneal donation for DMEK, rather than excluding them given the shortage of corneal donors.

Researchers conducted a retrospective analysis of 484 eyes that underwent DMEK, categorizing them based on the donor tissue type.

The risk of complications during preparation was notably higher in the pseudophakic group compared to the other types. Although no significant differences in visual acuity were observed across the groups, recovery of central corneal thickness took longer for pseudophakic grafts, although it normalized after 3 months. In addition, the overall endothelial cell count was lower in the pseudophakic group.

The study found no significant difference in rebubbling rates among the donor groups. The researchers notes that the risk of needing repeat keratoplasty was lower for phakic grafts compared to pseudophakic ones.

The authors concluded that while pseudophakic donor grafts present unique challenges during preparation and longer recovery times, they can yield comparable outcomes when no complications arise.

Reference
Trouvain AM, Szurman P, Wahl S, Siegel R, Boden KT, Seitz B, Fries FN, Rickmann A. Impact of Previous Cataract Surgery in Corneal Donors on the Outcome of Descemet Membrane Endothelial Keratoplasty. Cornea. 2024;43(7):844-852. doi: 10.1097/ICO.0000000000003423. Epub 2023 Nov 7. PMID: 39377776.

Share

Related Content

  • Cornea and External Disease

Quiz: The impact of blepharitis and conjunctivitis on quality of life

  • Cornea and External Disease

Phase 3 trial of cenegermin-bkbj for PCED enrolls first US patient

  • Cornea and External Disease

Cornea specialists identify key clinical signs linked to microbial keratitis subtypes

Cornea Update: Corneal Dystrophies & Related Conditions with an Update on Genetic Assessment and Treatment
  • Cornea and External Disease

Preventing complications of superficial keratectomy

  • Conference Roundup

Phase 1/2 CLARA study shows AURN001 improves BCVA compared with standard of care for corneal endothelial dysfunction

  • Conference Roundup

Epioxa crosslinking system has positive outcomes at 30 months in patients with keratoconus

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon